Compare Ascendis Pharma A/S (ASND) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Expedia Group Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Expedia Group Inc trades at $269.2 (market cap $32.51B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Expedia Group Inc pays a 0.65% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EXPE | |
|---|---|---|
Market Cap | $17.74B | $32.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $301.31 |
52-Week Low | $163.32 | $178.06 |
Enterprise Value | $18.11B | $31.42B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Expedia Group (EXPE) trades at $270.83, up 1.14% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.96 exceeding expectations by 39%. Revenue growth has accelerated from $11.7B in 2022 to $14.7B in 2025, while net income margins improved to 9.81%. Recent developments include the CarTrawler acquisition and AI initiatives, positioning the company for continued travel sector leadership.
Outlook remains positive with analyst consensus target of $285.44 offering 5.4% upside. Key opportunities include travel demand recovery and operational efficiency gains, while risks involve macroeconomic sensitivity and competitive pressures. The stock presents a balanced risk-reward profile with strong institutional support and improving financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
